https://www.kaziatx.com/ https://www.kaziatx.com/about-us https://www.kaziatx.com/about-us/management https://www.kaziatx.com/about-us/board-of-directors https://www.kaziatx.com/pipeline https://www.kaziatx.com/pipeline/paxalisib https://www.kaziatx.com/pipeline/pd-l1-protein-degrader https://www.kaziatx.com/pipeline/setdb1-inhibitor https://www.kaziatx.com/pipeline/evt801 https://www.kaziatx.com/pipeline/clinical-trials https://www.kaziatx.com/pipeline/posters-and-publications https://www.kaziatx.com/technology https://www.kaziatx.com/media-center https://www.kaziatx.com/media-center/news https://www.kaziatx.com/media-center/events https://www.kaziatx.com/media-center/in-the-news https://www.kaziatx.com/media-center/video-gallery https://www.kaziatx.com/media-center/asx-announcements https://www.kaziatx.com/investors https://www.kaziatx.com/investors/news-and-events/press-releases https://www.kaziatx.com/investors/news-and-events/ir-calendar https://www.kaziatx.com/investors/news-and-events/presentations https://www.kaziatx.com/investors/news-and-events/annual-general-meeting https://www.kaziatx.com/investors/news-and-events/email-alerts https://www.kaziatx.com/investors/company-information https://www.kaziatx.com/investors/company-information/management https://www.kaziatx.com/investors/company-information/contacts https://www.kaziatx.com/investors/company-information/faq https://www.kaziatx.com/investors/financial-results https://www.kaziatx.com/investors/stock-data/quote-and-chart https://www.kaziatx.com/investors/stock-data/historical-data https://www.kaziatx.com/investors/sec-filings/all-sec-filings https://www.kaziatx.com/investors/sec-filings/annual-reports https://www.kaziatx.com/investors/sec-filings/section-16-filings https://www.kaziatx.com/investors/governance https://www.kaziatx.com/investors/governance/board-of-directors https://www.kaziatx.com/investors/governance/board-committees https://www.kaziatx.com/investors/governance/governance-documents https://www.kaziatx.com/investors/asx-delisting https://www.kaziatx.com/investors/asx-delisting/how-to-convert-unlisted-shares-to-adss https://www.kaziatx.com/contact-us https://www.kaziatx.com/media-center/news/detail/218/kazia-therapeutics-limited-announces-pricing-of-up-to-120-million-public-offering 2026-08-28T07:30:13-04:00 https://www.kaziatx.com/media-center/news/detail/217/kazia-therapeutics-limited-announces-proposed-public-offering 2026-08-27T16:09:43-04:00 https://www.kaziatx.com/media-center/news/detail/216/kazia-therapeutics-reports-100-clinical-benefit-rate-in-initial-six-patients-treated-for-advanced-triple-negative-breast-cancer 2026-08-27T16:01:11-04:00 https://www.kaziatx.com/media-center/news/detail/219/kazia-therapeutics-announces-the-filing-of-provisional-patent-for-novel-strategy-supported-by-preclinical-data-to-prevent-metastatic-recurrence-in-triple-negative-breast-cancer 2026-08-28T10:29:08-04:00 https://www.kaziatx.com/media-center/news/detail/215/kazia-therapeutics-appoints-james-levine-as-chief-financial-officer 2026-06-02T07:30:03-04:00 https://www.kaziatx.com/media-center/news/detail/214/kazia-therapeutics-expands-ongoing-phase-1b-trial-of-paxalisib-in-advanced-breast-cancer 2026-05-26T07:30:04-04:00 https://www.kaziatx.com/media-center/news/detail/213/kazia-therapeutics-strengthens-scientific-leadership-with-appointment-of-dr-sudha-rao-as-chief-scientific-officer-to-lead-next-generation-oncology-platform 2026-04-15T08:00:16-04:00 https://www.kaziatx.com/media-center/news/detail/212/kazia-therapeutics-expands-oncology-platform-with-first-in-class-setdb1-inhibitor-drug-development-platform 2026-04-13T17:06:11-04:00 https://www.kaziatx.com/media-center/news/detail/85/kazia-therapeutics-announces-compelling-preclinical-and-translational-data-for-nuclear-pd-l1-degrader-ndl2 2026-03-05T10:10:13-05:00 https://www.kaziatx.com/media-center/news/detail/86/kazia-therapeutics-reports-encouraging-preliminary-clinical-responses-in-ongoing-phase-1b-study-of-paxalisib-in-late-stage-metastatic-triple-negative-breast-cancer 2026-03-05T10:10:13-05:00 https://www.kaziatx.com/media-center/news/detail/87/kazia-therapeutics-to-participate-in-j-p-morgan-healthcare-conference-week-clinical-and-translational-update-anticipated-before-month-end 2026-03-05T10:10:13-05:00 https://www.kaziatx.com/media-center/news/detail/88/kazia-therapeutics-regains-full-nasdaq-listing-compliance 2026-03-05T10:10:13-05:00 https://www.kaziatx.com/media-center/news/detail/89/kazia-therapeutics-highlights-new-clinical-and-translational-findings-demonstrating-paxalisibs-ability-to-reinvigorate-anti-tumor-immunity-across-multiple-advanced-breast-cancer-populations-including-tnbc-and-her2 2026-03-05T10:10:14-05:00 https://www.kaziatx.com/media-center/news/detail/90/kazia-therapeutics-announces-pricing-of-50-0-million-private-placement-of-equity-securities 2026-03-05T10:10:14-05:00 https://www.kaziatx.com/media-center/news/detail/91/kazia-therapeutics-achieves-initial-icr-immune-complete-response-in-metastatic-tnbc-and-delivers-q4-business-update-with-breakthroughs-across-breast-cancer-immuno-oncology-and-gbm-regulatory-strategy 2026-03-05T10:10:14-05:00 https://www.kaziatx.com/media-center/news/detail/92/kazia-therapeutics-to-request-fda-type-c-meeting-to-discuss-overall-survival-data-in-gbm-and-potential-nda-filing-in-alignment-with-fda-initiative-project-frontrunner 2026-03-05T10:10:14-05:00 https://www.kaziatx.com/media-center/news/detail/93/kazia-therapeutics-announces-collaboration-and-in-licensing-agreement-for-first-in-class-pd-l1-protein-degrader-program 2026-03-05T10:10:14-05:00 https://www.kaziatx.com/media-center/news/detail/94/kazia-therapeutics-announces-86-reduction-in-tumor-burden-in-expanded-access-case-of-metastatic-tnbc-patient-treated-with-paxalisib-immunotherapy-regimen 2026-03-05T10:10:14-05:00 https://www.kaziatx.com/media-center/news/detail/95/kazia-therapeutics-supports-australian-mrff-funded-project-developing-ai-driven-sequential-therapy-strategy-for-dipgdmg 2026-03-05T10:10:14-05:00 https://www.kaziatx.com/media-center/news/detail/96/kazia-therapeutics-reports-complete-ex-vivo-disruption-of-large-circulating-tumor-cell-clusters-in-stage-iv-her2-positive-breast-cancer-with-paxalisib-monotherapy 2026-03-05T10:10:14-05:00 https://www.kaziatx.com/media-center/news/detail/97/kazia-therapeutics-announces-2-million-private-placement-at-premium-to-market 2026-03-05T10:10:14-05:00 https://www.kaziatx.com/media-center/news/detail/98/kazia-therapeutics-reports-early-efficacy-data-from-first-triple-negative-breast-cancer-patient-receiving-paxalisib-combination-regimen-achieving-50-reduction-in-circulating-tumor-cells-in-phase-1b-trial 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/99/kazia-therapeutics-announces-transformative-preclinical-data-demonstrating-paxalisibs-potential-to-overcome-immunotherapy-resistance-in-triple-negative-breast-cancer-tnbc 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/100/kazia-therapeutics-announces-first-patient-dosed-in-phase-1b-trial-of-paxalisib-in-advanced-breast-cancer 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/101/kazia-therapeutics-highlights-recent-progress-and-provides-business-update 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/102/kazia-therapeutics-announces-sale-of-intellectual-property-and-trademarks-rights-for-cantrixil 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/103/kazia-therapeutics-and-the-hebrew-university-of-jerusalem-receives-a-grant-from-the-michael-j-fox-foundation-to-evaluate-the-therapeutic-potential-of-paxalisib-as-a-treatment-for-parkinsons-disease 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/104/kazia-therapeutics-announces-the-launch-of-a-groundbreaking-trial-with-paxalisib-in-combination-with-immunotherapy-in-women-with-advanced-breast-cancer 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/105/kazia-therapeutics-announces-closing-of-2-0-million-registered-direct-offering 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/106/kazia-therapeutics-announces-2-0-million-registered-direct-offering 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/107/kazia-therapeutics-provides-update-on-paxalisib-regulatory-pathway-following-type-c-meeting-with-fda 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/108/kazia-therapeutics-to-present-data-highlighting-synergistic-activity-between-paxalisib-and-immunotherapy-in-immunotherapy-resistant-triple-negative-breast-cancer-model-at-the-san-antonio-breast-cancer-symposium 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/109/kazia-therapeutics-announces-granting-of-type-c-meeting-with-fda-to-discuss-potential-next-steps-for-paxalisib-in-the-treatment-of-newly-diagnosed-glioblastoma-multiforme 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/110/kazia-therapeutics-announces-presentation-of-promising-phase-i-data-evaluating-concurrent-paxalisib-and-radiation-therapy-in-patients-with-solid-tumor-brain-metastases-or-leptomeningeal-metastases-harboring-pi3k-pathway-mutations-at-the-american-society-for-radiation-oncology-66th-annual-meeting 2026-03-05T10:10:15-05:00 https://www.kaziatx.com/media-center/news/detail/111/kazia-therapeutics-announces-presentation-of-evt801-clinical-data-at-15th-biennial-ovarian-cancer-research-symposium 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/112/kazia-executes-licensing-agreement-with-qimr-berghofer 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/113/kazia-therapeutics-announces-phase-iiiii-clinical-trial-results-for-paxalisib-in-glioblastoma 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/114/kazia-announces-upcoming-dipg-data-presentations-at-ispno-and-publication-in-european-journal-of-cancer 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/115/kazia-granted-180-day-extension-by-nasdaq-to-meet-the-minimum-bid-price-requirement 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/116/kazia-reports-successful-stage-1-completion-of-the-evt801-phase-1-clinical-trial-in-advanced-cancer-patients 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/117/kazia-therapeutics-licenses-paxalisib-to-sovargen-for-intractable-seizures-in-rare-central-nervous-system-diseases 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/118/kazia-announces-presentation-of-new-data-at-aacr-annual-meeting 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/119/kazia-therapeutics-reports-early-conclusion-of-clinical-trial-after-reaching-primary-endpoint 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/120/kazia-continues-board-renewal-with-two-new-appointments 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/121/kazia-therapeutics-announces-closing-of-2-million-registered-direct-offering 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/122/kazia-therapeutics-announces-2-million-registered-direct-offering 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/123/kazia-announces-non-binding-letter-of-intent-for-the-proposed-granting-of-rights-to-develop-and-commercialize-paxalisib-outside-of-oncology 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/124/kazia-provides-overview-of-paxalisib-related-presentations-from-the-society-of-neuro-oncology-2023-annual-meeting 2026-03-05T10:10:16-05:00 https://www.kaziatx.com/media-center/news/detail/125/kazia-announces-receipt-of-nasdaq-minimum-bid-notification 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/126/kazia-announces-the-release-of-pnoc022-clinical-study-abstract-highlighting-paxalisib-in-diffuse-midline-glioma-patients-ahead-of-the-society-of-neuro-oncology-2023-annual-meeting 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/127/kazia-announces-publication-in-molecular-cancer-therapeutics-highlighting-paxalisib-preclinical-data-in-melanoma 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/128/kazia-therapeutics-provides-preliminary-update-from-ongoing-phase-2-study-of-paxalisib-in-primary-cns-lymphoma 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/129/kazia-therapeutics-announces-clinical-data-at-esmo-2023-from-ongoing-phase-1-evt801-study 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/130/kazia-announces-voluntary-delisting-from-asx 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/131/kazia-therapeutics-announces-presentations-at-upcoming-scientific-meetings 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/132/kazia-therapeutics-announces-acceptance-of-late-breaking-abstract-and-oral-presentation-of-pnoc022-clinical-data-at-2023-society-for-neuro-oncology-annual-meeting 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/133/kazias-paxalisib-receives-fast-track-designation-from-fda-for-treatment-of-solid-tumor-brain-metastases-harboring-pi3k-pathway-mutations-in-combination-with-radiation-therapy 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/134/kazia-therapeutics-announces-phase-ii-clinical-study-to-investigate-paxalisib-in-recurrentprogressive-idh-mutant-grade-2-3-glioma 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/135/kazia-ceo-dr-john-friend-to-participate-in-white-house-cancer-moonshot 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/136/kazia-regains-compliance-with-nasdaq-minimum-bid-price-requirement 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/137/kazia-presents-new-data-for-paxalisib-and-evt801-at-aacr-annual-meeting 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/138/kazia-therapeutics-ceo-talks-4-5-million-capital-raise 2026-03-05T10:10:17-05:00 https://www.kaziatx.com/media-center/news/detail/139/kazia-raises-a4-5-million-to-progress-rd-programs 2026-03-05T10:10:18-05:00 https://www.kaziatx.com/media-center/news/detail/140/kazia-launches-preclinical-collaboration-with-qimr-berghofer-medical-research-institute-and-announces-patent-filing 2026-03-05T10:10:18-05:00 https://www.kaziatx.com/media-center/news/detail/141/kazia-announces-receipt-of-nasdaq-minimum-bid-notification 2026-03-05T10:10:18-05:00 https://www.kaziatx.com/media-center/news/detail/142/kazia-therapeutics-talks-positive-pre-clinical-data-for-evt801 2026-03-05T10:10:18-05:00 https://www.kaziatx.com/media-center/news/detail/143/compelling-preclinical-data-for-kazias-evt801-published-in-peer-reviewed-cancer-research-journal 2026-03-05T10:10:18-05:00 https://www.kaziatx.com/media-center/news/detail/144/kazia-to-present-paxalisib-data-in-adult-and-pediatric-brain-cancer-at-society-for-neuro-oncology-annual-meeting 2026-03-05T10:10:18-05:00 https://www.kaziatx.com/media-center/news/detail/145/kazias-paxalisib-demonstrates-positive-monotherapy-efficacy-signals-in-preclinical-models-of-melanoma 2026-03-05T10:10:18-05:00 https://www.kaziatx.com/media-center/news/detail/146/pnoc-clinical-study-of-kazias-paxalisib-in-childhood-brain-cancer-expands-internationally 2026-03-05T10:10:18-05:00 https://www.kaziatx.com/media-center/news/detail/147/kazia-therapeutics-to-present-at-hc-wainwright-24th-annual-global-investment-conference 2026-03-05T10:10:18-05:00 https://www.kaziatx.com/media-center/news/detail/148/kazia-to-present-final-data-from-paxalisib-phase-ii-study-in-glioblastoma-at-esmo 2026-03-05T10:10:18-05:00 https://www.kaziatx.com/media-center/news/detail/149/kazia-therapeutics-reports-promising-interim-data-from-combination-study-of-paxalisib-with-radiotherapy-in-treatment-of-brain-metastases 2026-03-05T10:10:18-05:00 https://www.kaziatx.com/media-center/news/detail/150/kazia-launches-new-scientific-advisory-board-comprised-of-world-leading-experts-in-brain-cancer 2026-03-05T10:10:19-05:00 https://www.kaziatx.com/media-center/news/detail/151/us-fda-awards-rare-pediatric-disease-designation-rpdd-to-paxalisib-for-atrt-a-rare-form-of-childhood-brain-cancer 2026-03-05T10:10:19-05:00 https://www.kaziatx.com/media-center/news/detail/152/us-fda-awards-orphan-drug-designation-odd-to-paxalisib-for-atrt-a-rare-form-of-childhood-brain-cancer 2026-03-05T10:10:19-05:00 https://www.kaziatx.com/media-center/news/detail/153/positive-data-for-paxalisib-in-two-childhood-brain-cancers-presented-at-20th-ispno-annual-meeting 2026-03-05T10:10:19-05:00 https://www.kaziatx.com/media-center/news/detail/154/phase-ii-study-of-paxalisib-in-brain-metastases-advances-to-expansion-stage-in-breast-cancer-brain-metastases-cohort 2026-03-05T10:10:19-05:00 https://www.kaziatx.com/media-center/news/detail/155/kazia-presents-positive-final-data-from-phase-ii-study-of-paxalisib-in-newly-diagnosed-glioblastoma-at-asco-conference 2026-03-05T10:10:19-05:00 https://www.kaziatx.com/media-center/news/detail/156/gbm-agile-opens-to-paxalisib-in-europe 2026-03-05T10:10:19-05:00 https://www.kaziatx.com/media-center/news/detail/157/kazia-therapeutics-to-present-at-upcoming-investor-conferences-hosted-by-hc-wainwright-and-ld-micro 2026-03-05T10:10:19-05:00 https://www.kaziatx.com/media-center/news/detail/158/kazia-marks-dipg-awareness-day-new-preclinical-data-in-dipg-to-be-presented-at-ispno-conference 2026-03-05T10:10:19-05:00 https://www.kaziatx.com/media-center/news/detail/159/kazia-to-present-final-data-from-paxalisib-phase-ii-study-in-glioblastoma-at-asco 2026-03-05T10:10:19-05:00 https://www.kaziatx.com/media-center/news/detail/160/kazia-therapeutics-announces-preclinical-data-presented-at-aacr-conference-by-johns-hopkins-university-showing-activity-of-paxalisib-in-paediatric-brain-tumours 2026-03-05T10:10:19-05:00 https://www.kaziatx.com/media-center/news/detail/161/two-abstracts-at-aacr-conference-present-detailed-study-design-and-innovative-biomarker-strategy-for-ongoing-phase-i-study-of-evt801-in-advanced-cancer 2026-03-05T10:10:19-05:00 https://www.kaziatx.com/media-center/news/detail/162/kazia-to-present-at-upcoming-investor-conference-and-aacr-annual-scientific-meeting 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/163/phase-ii-clinical-study-at-weill-cornell-medical-center-investigating-paxalisib-in-combination-with-metformin-and-a-ketogenic-diet-enrolls-first-patient 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/164/kazia-therapeutics-to-present-at-bio-ceo-conference 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/165/kazia-therapeutics-to-participate-in-edison-groups-global-healthcare-open-house-virtual-conference 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/166/kazia-therapeutics-to-present-at-hc-wainwright-bioconnect-conference 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/167/kazia-therapeutics-appoints-karen-krumeich-as-chief-financial-officer 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/168/kazia-announces-positive-final-data-from-phase-ii-clinical-study-of-paxalisib-in-newly-diagnosed-glioblastoma 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/169/gbm-agile-opens-to-paxalisib-in-canada 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/170/kazia-therapeutics-appoints-john-friend-md-as-chief-medical-officer 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/171/pnoc-study-in-childhood-brain-cancer-enrols-first-patient 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/172/kazia-enrols-first-patient-to-evt801-phase-i-clinical-trial 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/173/kazia-therapeutics-to-present-at-ld-micro-main-event 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/174/kazia-therapeutics-to-present-at-hc-wainwright-23rd-annual-global-investment-conference 2026-03-05T10:10:20-05:00 https://www.kaziatx.com/media-center/news/detail/175/kazia-calls-for-increased-focus-on-brain-cancer-research-this-gbm-awareness-day 2026-03-05T10:10:21-05:00 https://www.kaziatx.com/media-center/news/detail/176/kazia-provides-progress-update-on-paxalisib-and-evt801-clinical-programs 2026-03-05T10:10:21-05:00 https://www.kaziatx.com/media-center/news/detail/177/kazia-enters-clinical-collaboration-with-cornell-university-for-phase-ii-clinical-study-using-paxalisib-in-combination-with-ketogenic-diet-for-glioblastoma 2026-03-05T10:10:21-05:00 https://www.kaziatx.com/media-center/news/detail/178/study-of-paxalisib-in-primary-cns-lymphoma-at-dana-farber-cancer-institute-enrols-first-patient 2026-03-05T10:10:21-05:00 https://www.kaziatx.com/media-center/news/detail/179/kazia-therapeutics-to-present-at-ld-micro-invitational-xi 2026-03-05T10:10:21-05:00 https://www.kaziatx.com/media-center/news/detail/180/kazia-licenses-global-rights-to-evt801-a-novel-first-in-class-clinic-ready-vegfr3-inhibitor-from-evotec-se 2026-03-05T10:10:21-05:00 https://www.kaziatx.com/media-center/news/detail/181/kazia-licenses-rights-to-paxalisib-in-greater-china-to-simcere-a-leading-chinese-pharmaceutical-company 2026-03-05T10:10:21-05:00 https://www.kaziatx.com/media-center/news/detail/182/kazia-licenses-cantrixil-a-clinical-stage-first-in-class-ovarian-cancer-drug-candidate-to-oasmia-pharmacetical-ab 2026-03-05T10:10:21-05:00 https://www.kaziatx.com/media-center/news/detail/183/kazia-to-collaborate-with-pacific-pediatric-neuro-oncology-consortium-pnoc-for-new-paxalisib-combination-study-in-dipg 2026-03-05T10:10:22-05:00 https://www.kaziatx.com/media-center/news/detail/184/top-line-final-data-from-cantrixil-phase-i-study-confirms-prior-positive-efficacy-and-safety-signals 2026-03-05T10:10:22-05:00 https://www.kaziatx.com/media-center/news/detail/185/kazia-presents-further-paxalisib-data-at-sno-confirming-earlier-positive-safety-and-efficacy-signals-in-glioblastoma 2026-03-05T10:10:22-05:00 https://www.kaziatx.com/media-center/news/detail/186/kazia-executes-agreement-to-commence-gbm-agile-pivotal-study 2026-03-05T10:10:22-05:00 https://www.kaziatx.com/media-center/news/detail/187/kazia-enters-clinical-collaboration-with-dana-farber-cancer-institute-for-primary-cns-lymphoma 2026-03-05T10:10:22-05:00 https://www.kaziatx.com/media-center/news/detail/188/us-fda-awards-orphan-drug-designation-odd-to-paxalisib-for-malignant-glioma-including-dipg 2026-03-05T10:10:22-05:00 https://www.kaziatx.com/media-center/news/detail/189/us-fda-awards-orphan-drug-designation-odd-to-paxalisib-for-malignant-glioma-including-dipg 2026-03-05T10:10:22-05:00 https://www.kaziatx.com/media-center/news/detail/190/us-fda-awards-fast-track-designation-ftd-to-paxalisib-for-glioblastoma 2026-03-05T10:10:22-05:00 https://www.kaziatx.com/media-center/news/detail/191/us-fda-grants-rare-pediatric-disease-designation-rpdd-to-paxalisib-for-dipg 2026-03-05T10:10:22-05:00 https://www.kaziatx.com/media-center/news/detail/192/kazia-presents-further-paxalisib-and-cantrixil-data-at-aacr-reinforcing-positive-efficacy-signals-for-both-drugs 2026-03-05T10:10:23-05:00 https://www.kaziatx.com/media-center/news/detail/193/kazia-presents-interim-paxalisib-phase-ii-data-at-asco-showing-positive-overall-survival-signal 2026-03-05T10:10:23-05:00 https://www.kaziatx.com/media-center/news/detail/194/kazias-paxalisib-shows-positive-overall-survival-signal-in-phase-ii-glioblastoma-study 2026-03-05T10:10:23-05:00 https://www.kaziatx.com/media-center/events/detail/20260623-bio-international-convention 2026-08-28T14:16:01-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-094603/ea0303789-6k_kazia.htm 2026-08-28T06:10:52-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-094600/ea0303789-424b5_kazia.htm 2026-08-28T06:09:40-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-094426/ea0303701-424b5_kazia.htm 2026-08-27T16:49:15-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-094421/ea030368405-424b3_kazia.htm 2026-08-27T16:46:30-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-094418/ea030368404-424b3_kazia.htm 2026-08-27T16:44:21-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-094413/ea030368403-424b3_kazia.htm 2026-08-27T16:42:39-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-094409/ea030368402-424b3_kazia.htm 2026-08-27T16:39:30-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-094408/ea0303684-6k_kazia.htm 2026-08-27T16:38:26-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0000921895-26-002261/primary_doc.html 2026-08-19T18:40:37-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001193125-26-352951/primary_doc.html 2026-08-14T21:08:39-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001104659-26-097117/primary_doc.html 2026-08-14T16:28:39-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-081986/ea029943505-424b3_kazia.htm 2026-07-28T07:34:59-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-081985/ea029943504-424b3_kazia.htm 2026-07-28T07:34:03-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-081984/ea029943503-424b3_kazia.htm 2026-07-28T07:32:56-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-081983/ea029943502-424b3_kazia.htm 2026-07-28T07:32:00-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-081982/ea029943501-6k_kazia.htm 2026-07-28T07:30:57-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-076431/ownership.html 2026-07-08T17:00:06-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-076430/ownership.html 2026-07-08T16:59:38-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-076429/ownership.html 2026-07-08T16:59:15-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-076428/ownership.html 2026-07-08T16:58:41-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-076427/ownership.html 2026-07-08T16:58:18-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-076426/ownership.html 2026-07-08T16:57:53-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-071231/ownership.html 2026-06-23T18:48:04-04:00 https://www.kaziatx.com/investors/sec-filings/all-sec-filings/content/0001213900-26-071230/ownership.html 2026-06-23T18:47:53-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34456/kazia-presentation-to-biotech-showcase 2018-01-10T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34457/kazia-presentation-to-proactive-investors-ceo-series 2018-03-19T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34458/kazia-presents-at-gold-coast-investment-showcase 2018-06-21T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34459/kazia-shareholder-presentation 2018-07-16T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34460/presentation-to-finance-news-network-investor-event 2018-10-11T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34461/kazia-presents-to-ausbiotech-invest 2018-10-30T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34462/agm-presentations 2018-11-08T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34463/kazia-presentation-to-sno 2018-11-14T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34464/kazia-presentation-to-biotech-showcase 2019-01-07T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34465/kazia-presentation-to-proactive-investors 2019-02-18T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34466/kazia-presents-cantrixil-phase-i-data-at-aacr 2019-04-01T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34467/kazia-presents-to-gold-coast-investment-showcase 2019-06-25T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34468/kazia-presents-gdc-0084-at-eano 2019-09-20T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34469/kazia-presents-cantrixil-poster-at-esmo 2019-09-30T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34470/kazia-presents-to-ausbiotech-invest 2019-10-31T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34471/kazia-agm-presentations 2019-11-13T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34472/kazia-presents-to-switzer-investment-conference 2019-12-03T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34473/kazia-presents-at-biotech-showcase 2020-01-13T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34474/kazia-presents-to-finance-news-network 2020-04-20T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34475/kazia-presents-interim-paxalisib-data-to-asco 2020-06-01T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34476/kazia-presentation-to-tkirw 2020-06-16T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34477/kazia-presents-posters-at-aacr 2020-06-22T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34478/kazia-presents-to-hidden-gems-sharecafe-investor-webinar 2020-06-25T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34479/kazia-presents-to-h-c-wainwright-conference 2020-09-15T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34480/kazia-investor-presentation 2020-10-01T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34481/kazia-presents-to-hcw-israel-conference 2020-11-12T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34482/kazia-presentation-to-bell-potter-healthcare-conference 2020-11-26T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34483/kazia-presents-to-ld-micro-main-event 2020-12-14T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34484/kazia-presents-to-hcw-bioconnect 2021-01-05T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34485/kazia-presents-to-sharecafe-hidden-gems-webinar 2021-01-22T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34486/kazia-corporate-presentation 2021-04-19T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34487/evt801-in-licensing-deal-investor-conference-call-transcript 2021-04-21T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34488/kazia-corporate-presentation 2021-08-16T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34489/kazia-corporate-deck 2022-01-19T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34490/kazia-presentation-on-paxalisib-for-childhood-brain-cancer 2022-06-23T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34491/kazia-presentation-to-hcw-bioconnect 2022-09-14T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34492/kazia-presents-to-bell-potter-healthcare-conference 2022-11-09T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34493/kazia-corporate-update-and-corporate-presentation 2023-06-26T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34494/presentations-at-upcoming-scientific-meetings 2023-10-05T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34495/evt801-progress-update-presentation 2024-03-19T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34496/kazia-corporate-presentation 2024-04-12T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34497/kazia-corporate-presentation-may-2024 2024-05-30T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34498/kazia-corporate-presentation-november-2024 2024-11-04T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34499/kazia-corporate-presentation-january-2025 2025-02-03T00:00:00-05:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34500/annual-general-meeting-may-2025 2025-05-22T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34501/kazia-corporate-presentation-august-2025 2025-10-08T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34503/investor-fact-sheet-2026 2026-03-27T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34502/kazia-corporate-presentation-march-2026 2026-03-27T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34504/investor-fact-sheet-april-2026 2026-04-27T00:00:00-04:00 https://www.kaziatx.com/investors/news-and-events/presentations/detail/34505/corporate-overview-april-2026 2026-04-27T00:00:00-04:00 https://www.kaziatx.com/privacy-policy https://www.kaziatx.com/disclaimer https://www.kaziatx.com/sitemap https://www.kaziatx.com/accessibility-statement